Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Its lead product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Lorundrostat is being developed for the treatment of cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company operates in the United States and is dedicated to addressing conditions where aldosterone dysregulation plays a key role.

Mineralys Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MLYS. Its securities are traded in US Dollars (USD), reflecting its primary operations and headquarters in the United States.

Mineralys Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on research and development of novel therapies for cardiorenal conditions, leveraging biotechnology approaches to create targeted treatments for diseases linked to aldosterone dysregulation.

Mineralys Therapeutics is headquartered in Radnor, Pennsylvania, United States. The company was incorporated in 2019 and was originally known as Catalys SC1, Inc. before rebranding to Mineralys Therapeutics in May 2020. Its operations are centered in the US, where it develops its lead candidate lorundrostat for cardiorenal diseases.